JNJ vs RDGT

JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.

Despite a stable Piotroski F-Score of 6/9, RDGT is in a state of catastrophic financial and market collapse. The stock has plummeted from a 52-week high of $760.50 to $2.23, representing a near-total loss of value across all timeframes. Most critically, the provided earnings data is over a decade old (dating back to 2011), suggesting a complete failure in current financial reporting and transparency. The combination of negative revenue growth and a 0/100 technical trend indicates a terminal decline.